ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1933

Specialist Wound Care Services Provision and Sharp Debridement Practices for Digital Ulcers (DU) Management in Systemic Sclerosis (SSc): An International Survey
Abstract Number: 1781

Specific gut microbiome remodeling occurs after induction of OA via DMM surgery compared to sham surgery
Abstract Number: 2434

Specificity of Cell-bound T Cell Biomarkers (TC4d, TIgG, TIgM) in Differentiating SLE from ANA-Associated Rheumatic Diseases
Abstract Number: 0523

SPECTREM: Guselkumab Significantly Improves Patient Reported Outcomes at Week 16 in Participants with Low Body Surface Area, Moderate Psoriasis with Special Sites Involvement
Abstract Number: 2025

Spectrum of Autoantibodies in CNS Demyelinating Diseases: Clinical, Laboratory and Imaging Associations
Abstract Number: 1715

Spondyloarthritis and Psoriatic Arthritis Patients Under Immunosuppressive Conventional and Biologic DMARDs: Favorable Disease Safety and Attenuated Immunogenicity Following Recombinant Herpes Zoster Vaccination
Abstract Number: 0051

Spp1+ Macrophages Are Specifically Enriched in Arthritic Joints and Associated with Abnormal Bone Metabolism in Collagen-Induced Arthritis Mice
Abstract Number: 0833

Sputum Anti-CCP-IgA and NET-Associated Proteins Predict Risk and Timing of the Transition From Systemic Autoimmunity to Classified RA
Abstract Number: 0811

SSc Skin Cell Atlas: a Scalable Web Portal for scRNA-Seq Analysis
Abstract Number: 0289

Standardized Interoperable Data Collection for Myositis Research: Developing Common Data Elements for Myositis Disease Activity Core Set Measures
Abstract Number: 1691

Standardizing DXA Screening in Childhood-Onset Systemic Lupus Erythematosus at A Single Center: A Quality Improvement Initiative Using a Decision-Tree Algorithm
Abstract Number: 2377

Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus
Abstract Number: 2077

Statin-Associated Immune-Mediated Necrotizing Myopathy in Native Americans
Abstract Number: 2040

Steroid Psychosis and Neuropsychiatric Symptoms induced by Corticosteroid Injection in Rheumatology Patients
Abstract Number: 1251

Steroids and Me (Sam): engaging and educating steroid-treated patients via patient advocacy partnerships and internet search channels.

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].